Latin America Research Stats
Applied Clinical Trials
Starting with Eastern European sites in the 1990s, companies have increasingly selected investigator sites outside of North America and Western Europe.
Starting with Eastern European sites in the 1990s, companies have increasingly selected investigator sites outside of North America and Western Europe. Recently, drug development organizations have also been recruiting sites and enrolling patients in more remote locations such as Asia, India, and Latin America. Little research has been done on the attitudes of investigators in these newer geographies: why they participate in clinical trial research, what they like and dislike about their clinical trial experiences, and their thoughts about organizations conducting these clinical studies. TTC and the University of the Sciences in Philadelphia conducted a 4,000 multinational site survey.
The overall response distribution in Latin America closely followed the distribution of sites by country and therapeutic areas recorded in ClinicalTrials.gov. The complete questionnaire and respondent answers can be found online.
Latin America and US investigators emphasize the importance of medical innovation as grounds for their involvement in clinical studies. For Latin American physicians, this interest in innovation holds whether the research directly touches their patients or not. Latin American investigators are especially keen to share their clinical trial derived knowledge with other physicians.
—TTC and the University of Sciences in Philadelphia (for more information, contact help@ttc-llc.com).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
